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Abstract
Objectives: To evaluate the prevalence of human papillomavirus (HPV) types, and risk factors for
HPV positivity across cervix, vagina and anus, we conducted a study among 138 women with human
immunodeficiency virus (HIV).
Goal: Compare the prevalence of different HPV types and the risk factors for HPV positivity in
three sites.
Results: The most frequently detected HPV types in all sites were, in decreasing order, HPV16,
53, 18, 61 and 81. Agreement between the cervix and vagina was good (kappa 0.60 – 0.80) for
HPV16 and 53 and excellent (Kappa > 0.80) for HPV18 and 61. HPV positivity was inversely
associated with age for all combinations including the anal site.
Conclusion: In HIV positive women, HPV18 is the most spread HPV type found in combinations
of anal and genital sites. The relationship of anal to genital infection has implications for the
development of anal malignancies. Thus, the efficacy of the current HPV vaccine may be considered
not only for the cervix, but also for prevention of HPV18 anal infection among immunossuppressed
individuals.
Background
More than 1.7 million people were living with human
immunodeficiency virus (HIV) infection in Latin America
at the end of 2004, and Brazilian women made up more
than one-third (610,000) of this population [1]. Among
women from 15–24 years of age, the prevalence of HIV
infection in Brazil is estimated to be 0.5%. With the
advent of antiretroviral drugs in Brazil, median survival
time for people diagnosed with AIDS has increased from
18 to 58 months [2].
Epidemiological and laboratory data have demonstrated
that persistent infection with high-risk human papilloma-
virus (HPV) types (like 16, 18, 31, 33, 39, 45, 52, 53, 56,
Published: 14 March 2008
Infectious Agents and Cancer 2008, 3:5 doi:10.1186/1750-9378-3-5
Received: 26 September 2006
Accepted: 14 March 2008
This article is available from: http://www.infectagentscancer.com/content/3/1/5
© 2008 Gonçalves et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Infectious Agents and Cancer 2008, 3:5 http://www.infectagentscancer.com/content/3/1/5
Page 2 of 7
(page number not for citation purposes)
58, 59, 66, 68, 73, 82) is an essential step in the develop-
ment of invasive cervical cancer and the majority of anal
cancer [3]. Compared to HIV-negative women, HIV-posi-
tive women have an increased incidence and persistence
of HPV infection and a concomitant increased risk of
developing squamous intraepithelial lesions and cervical
cancer [4-7].
In addition, compared to HIV-negative women, HIV-pos-
itive women show a higher occurrence of multiple-type
HPV infection [8-10] and a relatively lower proportion of
HPV16 [11]. Little information is available on the con-
comitant prevalence of HPV infection in different ano-
genital sites [12], notably in the anal area [13,14].
In this study we have compared the prevalence of different
HPV types and the risk factors for HPV positivity in three
sites (i.e., cervical, vaginal and anal area).
Methods
Patients
Study methods have been reported elsewhere [8]. Briefly,
a cross-sectional study was conducted among 138 HIV-
positive women, aged 19–57 (mean age = 31 years), who
attended the Center of Reference in AIDS of Santos, São
Paulo, Brazil between June 1996 and April 1997. Patients
who reported previous hysterectomy, virgins or those who
were not able to provide an informed consent form were
excluded from the study. All women underwent HIV sero-
logical testing with Western blot confirmation (Cam-
bridge Biotech Corporation, Worcester, Massachusetts,
USA). CD4 cell count was performed on the date of the
visit or within three months thereafter. CD4 counts were
> 500 cells/mm3 in 24.6% women, between 200–499
cells/mm3 in 37.0%, and < 200 cells/mm3 in 38.4%.
The same gynecologist applied a standard questionnaire
for all patients to elicit information on sociodemographic
characteristics, smoking habits, history of drug addiction,
sexual behavior and use of condom. The Ethics Commit-
tee of the Medical School of the University of São Paulo,
Brazil, approved the study protocol, and all participants
signed informed consent forms.
Sample collection
The same gynecologist collected exfoliated cells from 1)
ectocervix, 2) vagina and 3) anal area, in that order, with
separate sterile brushes, and stored in separate flasks in
phosphate-buffered saline solution (PBS). To obtain sam-
ples for anal collection, individual disposable brushes
moistened in sterile PBS were inserted into the anal canal
and were rotated 360° as they were withdrawn.
HPV detection and typing
After collection, cells remaining in the collection devices
were washed out into a sterile buffered solution and kept
at -20°C for HPV analysis. Beta-globin amplification was
used to assess specimen adequacy for HPV DNA detec-
tion. Polymerase chain reaction (PCR)-based assays were
carried out in the Laboratorio de Patologia e Hemoterapia
do Hospital do Cancer, Fundação Antonio Prudente, São
Paulo, Brazil [15].
PCR-positive samples were further typed by restriction
fragment length polymorphism according to Bernard et al.
[16], allowing the recognition of more than 42 HPV types
(HPV6,11, 13, 16, 18, 26, 31, 32, 33, 34, 35, 39, 40, 42,
44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 64, 66,
67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, LVX100 and
CP6108). The following restriction enzymes were used:
Bam HI, Dde I, Hae III, Hinf I, Pst I, Rsa I and Sau 3a I
(Gibco BRL-Life Technologies, Los Angeles, California,
USA). The identification of HPV types was performed by
comparing the pattern of amplified bands with those
attributed to each virus type. HPV types were classified as
high-risk (or probably high-risk) and low-risk types as in
Muñoz et al. [17]. Other HPV types that could not be iden-
tified in this study were considered unidentified (HPVX).
Statistical analysis
The Kappa statistic was used to calculate the agreement
between HPV positivity at the cervical vs vaginal or anal
sites. The concordance rate was considered fair to good if
Kappa values were between 0.60–0.80, and excellent if
greater than 0.80. Agreement for any HPV type is defined
as presence of at least one common HPV type in the 2 or
3 combined sites. ORs for detection of HPV infection and
corresponding 95% CIs were calculated separately for
each anogenital site and for each combination of 2 or 3
sites by means of unconditional regression equations
adjusted for age (< 25, 25–34, ≥ 35). The analyses were
repeated with adjustment for age and CD4 count (< 200,
200–499, ≥ 500).
Results
HPV prevalence by anogenital site
The prevalence of HPV infection among HIV-positive
women did not differ significantly between the three ano-
genital sites under study. The prevalence was 61.6% in the
cervix, 65.9% in the vagina, and 63.7% in the anal area.
The same similarity is seen when high-risk HPV types are
considered, in the cervix (36.2%), vagina (42.8%) and the
anal area (43.1%). In respect to low-risk HPV types, the
prevalence was 34.1% in the cervix, 35.5% in the vagina
and 33.3% in the anal area. Multiple HPV infections
occurred in 41.2% of HPV-positive cervical samples,
48.4% of HPV-positive vaginal samples and 44.6% of
HPV-positive anal samples. The prevalence of HPV types
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according to the risk category in the studied female popu-
lation was described elsewhere [18].
In the cervix, the most frequent high-risk HPV types were
HPV16 and 53 (n = 13 each type) and HPV18 (n = 12)
(Table 1). HPV61 and 81 were the most frequent low-risk
HPV types (n = 11 and 9 respectively). For 9.4% of the
samples the HPV type could not be characterized.
Similarly, in the vagina, the most frequent high-risk HPV
types detected were HPV16, 53 and 18 (n = 17, 15 and 12,
respectively) (Table 1), while the most frequent low-risk
HPV types were HPV61 and 81 (n = 11 for each). Thirteen
% of vaginal samples were HPV positive but the HPV type
could not be characterized.
Table 1: Prevalence of 23 HPV types by collected site among 138 HIV-positive women. Santos, São Paulo, Brazil, 1996–1997
Site
Cervix Vagina Anala
Single Multiple Total (%) Single Multiple Total (%) Single Multiple Total (%)
HPV - 53 (38.4) 47 (34.1) 37 (36.3)
HPV + 50 35 85 (61.6) 47 44 91 (65.9) 36 29 65 (63.7)
HR HPV+ 23 28 51 (37.0) 25 34 59 (42.8) 16 28 44 (43.1)
LR HPV+ 24 23 47 (34.1) 19 30 49 (35.5) 15 20 35 (34.3)
High-risk
16 7 6 13 (9.4) 6 11 17 (12.3) 4 5 9 (8.8)
18 4 8 12 (8.7) 4 8 12 (8.7) 2 10 12 (11.8)
31 0 5 5 (3.6) 1 5 6 (4.3) 2 1 3 (2.9)
33 3 4 7 (5.1) 1 7 8 (5.8) 2 4 6 (5.9)
39 0 1 1 (0.7) 1 0 1 (0.7) 0 1 1 (1.0)
45 0 2 2 (1.4) 0 2 2 (1.4) 0 1 1 (1.0)
52 0 1 1 (0.7) 0 2 2 91.4) 0 0 0 (0.0)
53 5 8 13 (9.4) 7 8 15 (10.9) 4 9 13 (12.7)
56 1 0 1 (0.7) 1 1 2 (1.4) 0 1 1 (1.0)
58 1 2 3 (2.2) 1 2 3 (2.2) 1 2 3 (2.9)
59 1 0 1 (0.7) 0 0 0 (0.0) 0 0 0 (0.00
66 0 3 3 (2.2) 0 3 3 (2.2) 0 4 4 (3.9)
68 1 1 2 (1.4) 3 1 4 (2.9) 1 0 1 (1.0)
73 0 1 1 (0.7) 0 1 1 (0.7) 0 0 0 (0.0)
82 0 2 2 (1.4) 0 2 2 (1.4) 0 0 0 (0.0)
Subtotal 23 44 67 25 53 78 16 38 54
Low-risk
6 3 1 4 (2.9) 2 2 4 (2.9) 5 3 8 (7.8)
11 3 4 7 (5.1) 2 5 7 (5.1) 1 5 6 (5.5)
32 0 1 1 (0.7) 0 1 1 (0.7) 0 0 0 (0.0)
34 1 0 1 (0.7) 1 0 1 (0.7) 1 0 1 (1.0)
40 0 2 2 (1.4) 2 2 4 (2.9) 0 2 2 (1.8)
54 1 1 2 (1.4) 1 2 3 (2.2) 0 1 1 (1.0)
61 4 7 11 (8.0) 3 8 11 (8.0) 2 6 8 (7.3)
62 0 1 1 (0.7) 0 1 1 (0.7) 2 1 3 (2.7)
64 0 1 1 (0.7) 0 0 0 (0.0) 1 0 1 (1.0)
67 2 0 2 (1.4) 0 1 1 (0.7) 0 0 0 (0.0)
69 2 0 2 (1.4) 2 1 3 (2.2) 1 0 1 (1.0)
70 1 0 1 (0.7) 0 1 1 (0.7) 0 0 0 (0.0)
71 2 0 2 (1.4) 1 1 2 (1.4) 1 0 1 (1.0)
72 0 2 2 (1.4) 1 3 4 (2.9) 0 1 1 (1.0)
81 2 7 9 (6.5) 2 9 11 (8.0) 0 5 5 (4.6)
83 2 4 6 (4.3) 1 3 4 (2.9) 1 2 3 (2.7)
84 1 0 1 (0.7) 1 0 1 (0.7) 0 1 1 (1.0)
Subtotal 24 31 55 19 40 59 15 27 42
Unknown 3 10 13 (9.4) 3 15 18 (13.0) 5 7 12 (11.8)
aPresented for 102 HIV-positive women. HPV = human papillomavirus; HIV = human immunodeficiency virus; HR = High-risk; LR = low-risk
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In the anal area, the most frequently detected high-risk
HPV types were, in decreasing order, HPV53 (n = 13), 18
(n = 12), and 16 (n = 9). The most frequent low-risk HPV
types were HPV 61 and 6 (n = 8 for each). In 11.8% of anal
samples the HPV type could not be characterized. HPV6,
but not HPV11, tended to be more frequent in the anal
area than in the cervix or vagina (7.8% in the anal area vs
2.9% in each other site).
In respect to cervical and vaginal sites, agreement for any
HPV type positivity was 78.3% (Kappa value = 0.53 for
any type) and varied from 92.8% (HPV16) to 98.6%
(HPV61 and HPV6). Kappa values above 0.80 were found
for HPV18, 33 and 61. When cervical and anal sites were
compared, agreement for positivity for any HPV type was
found in 68.6% of women (Kappa value = 0.31) (Table 2).
The Kappa value was particularly low for HPV16 (0.11),
but was relatively elevated for HPV18 (0.69), especially
concerning the combination among the three sites (0.72).
Risk factors for associations between sites for any HPV 
positivity
As shown in Table 3, HPV positivity were inversely associ-
ated with age in three combinations of anogenital sites
(cervical+anal; vaginal+anal and cervical+vaginal+anal),
all of them including anal site. No association emerged in
any site between HPV positivity and smoking habits, his-
tory of drug addiction, commercial sex work and condom
use, and number of years since HIV diagnosis.
Anal intercourse showed an association of borderline sta-
tistical significance in the combination vaginal + anal for
HPV positivity (OR: 2.4; 95% CI: 0.97–6.0), but not else-
where. Nevertheless, condom use did not show associa-
tions with HPV positivity at all sites.
Discussion
Approximately two-thirds of HIV-positive women in our
study from Brazil were infected by HPV and the preva-
lence of HPV infection was similar in the cervix, vagina
and anal area. This also held true for the prevalence of the
most frequently detected individual HPV types, notably
HPV11, 16, 18, 53 and 61, and for the frequency of mul-
tiple-type infections. However, the same HPV type(s) were
not always present in the three examined anogenital areas
and the agreement in the detection of individual types was
better between the cervix and the vagina than between the
cervix and the anal area. The type most frequently detected
at all three sites was HPV18, mainly on account of its high
prevalence in the anal area. Recently, Castle et al. [19]
reported that some HPV types (e.g., HPV61, 71 and 72),
were more frequently detected in vaginal specimens from
hysterectomized women compared to those who had not
undergone hysterectomy. Simultaneous HPV infection in
different anogenital sites is considered a risk factor for the
concomitant occurrence of anal and cervical lesions, espe-
cially in HIV-positive women [20-22].
The factors most clearly associated with HPV positivity
among HIV-positive women in our study agree with find-
ings from HIV-negative women [23,24]. Although the
small number of women available did not allow most pre-
sented ORs to reach statistical significance, we did show
higher HPV positivity below age 25 than at age 35 or
older, as well as among women who reported two recent
sexual partners or more. These findings are consistent
with the report that recent sexual partners are a stronger
determinant of HPV positivity than the lifetime number
of sexual partners [25]. No consistent relationship
between HPV positivity and smoking habits or condom
use have emerged among HIV-negative women [23,24].
Two characteristics stand out as being more strongly asso-
ciated with HPV positivity in the anal area than in the cer-
vix and vagina, one being history of anal intercourse. This
finding suggests that anal infection is associated among
women, as it is among bisexual and homosexual men, to
direct HPV exposure [22,26]. Anal infection, however, can
Table 2: Agreement of HPV type detection by collected site among 138 HIV-positive women. Santos, São Paulo, Brazil: 1996–1997
Cervix: Vagina Cervix: Anusa Cervix, Vagina, Anusa
HPV type Cervix only Vagina only Both Agreement 
(Kappa 
value)
Cervix only Anal only Both Agreement 
(Kappa 
value)
Any of the 
three
All three Agreement 
(Kappa 
value)
16 3 7 10 92.8 (0.63) 9 7 2 84.3 (0.11)b 21 2 79.4 (0.32)
18 2 2 10 97.1 (0.82) 2 4 8 94.1 (0.69) 14 7 92.2 (0.72)
53 2 4 11 95.7 (0.76) 8 9 4 83.3 (0.23) 22 4 81.4 (0.45)
6 1 1 3 98.6 (0.74) 0 5 3 95.1 (0.52) 8 2 94.1 (0.55)
11 2 2 5 97.1 (0.70) 3 5 1 92.2 (0.16) 8 1 91.2 (0.33)
61 1 1 10 98.6 (0.90) 6 5 3 89.2 (0.29) 13 3 89.2 (0.54)
Any type 12 18 73 78.3 (0.53) 17 15 50 68.6 (0.31) 83 45 59.8 (0.40)
aAvailable for 102 women only; bNon-significant Kappa value. HPV = human papillomavirus; HIV = human immunodeficiency virus.
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Table 3: ORs ofHPV positivity and corresponding 95% CIs according to selected characteristics among 138 HIV-positive womena. Santos, São Paulo, Brazil, 1996–1997
Cervical+Vaginal Cervical+Analb Vaginal+Analb Cervical+Vaginal+Analb
Tot. No Pos. (%) ORc 95% CI Tot. No Pos. (%) ORc 95% CI Tot. No Pos. (%) ORc 95% CI Tot. No Pos. (%) ORc 95% CI
Age (years)
≥ 35 39 38.5 1 30 10.0 1 30 13.3 1 30 6.7 1
25–34 75 49.3 1.6 0.7–3.4 55 27.3 3.4 0.9–12.8 55 34.6 3.4 1.0–11.3 55 27.3 5.3 1.1–24.8
< 25 24 58.3 2.2 0.8–6.3 17 47.1 8.0 1.7–36.8 17 41.2 4.6 1.1–19.0 17 35.3 7.6 1.3–43.8
p for trend 0.12 0.006 0.03 0.02
Tobacco smoking
Never smoker 44 45.5 1 32 31.3 1 32 31.3 1 32 21.9 1
Ex-smoker 33 45.5 1.1 0.4–2.8 26 30.8 1.1 0.3–3.8 26 34.6 1.2 0.4–3.7 26 30.8 1.7 0.5–6.1
Current smoker 61 50.8 1.3 0.6–3.0 44 18.2 0.5 0.2–1.7 44 25.0 0.8 0.3–2.2 44 18.2 0.9 0.3–2.9
p for trend 0.46 0.22 0.52 0.60
Drug addict
Never 79 45.6 1 62 25.8 1 62 25.8 1 62 21.0 1
Ex 36 52.8 1.3 0.6–2.8 24 29.2 1.1 0.4–3.2 24 45.8 2.2 0.8–6.2 24 29.2 1.4 0.5–4.2
Current 23 47.8 1.0 0.4–2.7 16 18.8 0.7 0.2–2.9 16 18.8 0.6 0.2–2.6 16 18.8 0.8 0.2–3.5
p for trend 0.80 0.70 0.99 0.98
Years since HIV diagnosis
≤ 1 54 46.3 1 40 27.5 1 40 32.5 1 40 22.5 1
2–4 43 39.5 0.8 0.4–1.9 34 60.529.4 1.3 0.4–3.8 34 32.4 1.0 0.4–2.8 34 26.5 1.3 0.4–4.2
≥ 5 39 56.4 1.8 0.7–4.2 26 19.2 0.7 0.2–2.8 26 23.1 0.5 0.2–1.9 26 19.2 0.8 0.2–3.1
p for trend 0.25 0.73 0.38 0.81
CD4 count/mm3
≥ 500 34 41.2 1 20 15.0 1 20 15.0 1 20 10.0 1
200–499 51 49.0 1.8 0.7–4.7 39 23.1 4.2 0.8–22.2 39 30.8 4.8 1.0–22.7 39 23.1 5.7 0.9–34.1
< 200 53 59.9 1.8 0.7–4.6 43 32.6 5.9 1.2–28.6 43 34.9 5.0 1.1–22.4 43 27.9 6.2 1.1–34.9
p for trend 0.24 0.03 0.06 0.06
Commercial sex worker
Never 107 46.7 1 82 24.4 1 82 26.8 1 82 20.7 1
Ever 31 51.6 1.2 0.5–2.6 20 30.0 1.2 0.4–3.8 20 40.0 1.7 0.6–4.8 20 30.0 1.5 0.5–4.6
Lifetime number of sexual 
partners
≤ 2 34 41.2 1 26 26.9 1 26 30.8 1 26 26.9 1
3–5 44 52.3 1.5 0.6–3.8 35 25.7 0.9 0.3–2.9 35 25.7 0.7 0.2–2.3 35 17.1 0.5 0.1–1.8
≥ 6 60 48.3 1.2 0.5–3.0 41 24.4 0.7 0.2–2.3 41 31.7 0.8 0.3–2.6 41 24.4 0.7 0.2–2.2
p for trend 0.63 0.32 0.85 0.53
Recent sexual partnersd
0 48 43.8 1 42 21.4 1 42 26.2 1 42 21.4 1
1 74 47.3 1.0 0.5–2.1 51 25.5 0.8 0.3–2.4 51 27.5 0.8 0.3–2.0 51 19.6 0.6 0.2–1.7
≥ 2 13 76.9 3.5 0.8–15.0 9 44.4 2.2 0.5–10.7 9 55.6 2.6 0.5–12.0 9 44.4 2.0 0.4–9.5
p for trend 0.21 0.56 0.52 0.83
Condom used
Yes 69 47.8 1 47 25.5 1 47 27.7 1 47 19.2 1
No 20 60.0 1.7 0.6–4.8 13 38.5 2.0 0.5–7.6 13 46.2 2.4 0.7–8.8 13 38.5 2.9 0.7–11.6
Anal intercourse
Never 66 48.5 1 51 19.6 1 51 19.6 1 51 19.6 1
Ever 72 47.2 0.9 0.5–1.8 51 31.4 1.7 0.6–4.3 51 39.2 2.4 0.97–6.0 51 25.5 1.2 0.5–3.2
aSome figures do not add up to the total due to missing values; bPresented for 102 HIV-positive women; cAdjusted for age. HPV = human papillomavirus; d relative to the last 6 months preceding interview; HIV = 
human immunodeficiency virus; OR = odds ratio; CI = confidence intervals.
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also be detected in women who do not report anal inter-
course, particularly if a concomitant infection occurs at a
genital site [27,28]. The other factor that appeared more
strongly associated with anal than cervical or vaginal HPV
infection was low CD4 counts, thus suggesting that
immunosupression may particularly facilitate HPV infec-
tion and maybe persistence in the anal area.
One of the limitations of this work is its small sample size.
As a consequence, many relatively strong associations did
not attain statistical significance. Furthermore, the cross-
sectional design does not allow for the capture of the
dynamic nature of HPV infections. One of the strengths of
this study is the wide range of HPV types tested for at dif-
ferent anogenital sites in HIV-positive women.
In conclusion, our study showed that high prevalences of
HPV infection can be found in the entire lower genital
tract in HIV-positive women. In particular, the anal area
may represent a reservoir of HPV infection, notably HPV6
and 18. It will thus be important to evaluate the efficacy
of the current vaccine against HPV [29,30] to prevent not
only HPV infection in the cervix but also in the anal area,
among immunosuppressed individuals.
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